WHO Pharmaceuticals Newsletter 1998, No. 03&04
(1998; 18 pages)
Table of Contents
Open this folder and view contentsRegulatory actions
Open this folder and view contentsDrug surveillance
Open this folder and view contentsNew developments
View the documentRecent approvals
Open this folder and view contentsMedical devices
Close this folderGeneral information
View the documentAdvertising of medicinal drugs in the media - regulations
View the documentContainer and closure testing in lieu of sterility testing - draft guidance available
View the documentExtended release oral dosage forms - draft guidance available
View the documentHuman plasma-derived biological products or animal plasma or serum-derived products - draft guidance available
View the documentIron-containing supplements and drugs - small entity compliance guidance available
View the documentMedication errors - the "look-alike/sound alike" problem: name confusion
View the documentMedication errors: esmolol - another fatal case
Open this folder and view contentsVeterinary medicine

Container and closure testing in lieu of sterility testing - draft guidance available

United States of America. The Food and Drug Administration has announced the availability of a draft guidance document entitled "Guidance for Industry: Container and Closure Integrity Testing in lieu of Sterility Testing as a component of the Stability Protocol for Sterile Products", which is intended to provide recommendations and offer alternative methods for sterility testing to confirm the integrity of container and closure systems for sterile biological products, human and veterinary drugs, and medical devices. The draft guidance applies only to the replacement of the sterility test with an appropriate container and closure integrity test in the stability protocol, and is not offered as a replacement for sterility testing for product release.

Copies of the guidance may be obtained from the Dockets Management Branch (HFA-305), Food and Drug Administration, 1401 Rockville Pike, Rockville MD 20852-1448, USA (with one self-addressed adhesive label) or from the Internet at: http://www.fda.gov/cber/guidelines.htm.

Reference: Federal Register 63(18): 4272-3 (1998).

to previous section
to next section
The WHO Essential Medicines and Health Products Information Portal was designed and is maintained by Human Info NGO. Last updated: October 29, 2018